![]() |
市場調査レポート
商品コード
1749727
質量分析(MS)の世界市場:製品別、技術別、アプリケーション別、エンドユーザー別、地域別、機会、予測、2018年~2032年Global Mass Spectrometry Market Assessment, By Product, By Technology, By Application, By End-user, By Region, Opportunities and Forecast, 2018-2032F |
||||||
カスタマイズ可能
|
質量分析(MS)の世界市場:製品別、技術別、アプリケーション別、エンドユーザー別、地域別、機会、予測、2018年~2032年 |
出版日: 2025年06月17日
発行: Market Xcel - Markets and Data
ページ情報: 英文 232 Pages
納期: 3~5営業日
|
世界の質量分析(MS)市場は、2025~2032年の予測期間中にCAGR 6.92%を記録し、2024年の70億1,000万米ドルから2032年には119億7,000万米ドルに成長すると予測されています。臨床診断検査とともに、製薬・バイオテクノロジー分野でのアプリケーションの増加が、質量分析(MS)の世界市場を拡大しています。
質量分析(MS)市場は、ライフサイエンス診療や医療薬への投資の増加により、世界的に堅調な拡大を見せています。プロテオミクスとメタボロミクスにおける研究の進展と並んで、装置の感度と小型化における技術的な改善により、さまざまな産業における質量分析(MS)の採用が拡大し続けています。バイオテクノロジーと製薬セクターは、医薬品開発、品質管理評価、バイオマーカー探索プロセスにおいて質量分析(MS)技術に依存する重要な市場セクターです。この市場は、環境検査や食品安全モニタリングのために厳しくなっている規制要件から利益を得ています。ハイブリッドシステムとユーザーフレンドリーなインターフェースの革新により、運用の複雑さと資本経費が削減され続けており、質量分析(MS)技術が市場でより利用しやすくなっています。マーケットプレースには、戦略的提携や技術的進歩を通じて製品レンジを拡大する確立された組織が含まれます。科学研究分野は、複数の部門にわたる工業的品質管理業務とともに、質量分析(MS)に大きく依存しており、将来の成長に向けて分析機器における主導的地位を確保しています。
例えば、2024年12月には、F. Hoffmann-La Roche LtdがCoba Mass Specソリューションをリリースし、ルーチンラボ向けに完全自動化されたIVDR準拠システムを提供しています。標準化された臨床用MSソリューションが台頭してきた背景には、検査メニューを拡充するハイスループットシステムに対する需要の高まりがあります。
Global mass spectrometry market is projected to witness a CAGR of 6.92% during the forecast period 2025-2032, growing from USD 7.01 billion in 2024 to USD 11.97 billion in 2032. An increasing number of applications within the pharmaceutical and biotechnology sectors, along with clinical diagnostic testing, are expanding the global market for mass spectrometry.
Mass spectrometry markets globally show robust expansion owing to an increase in investment in life sciences practices and healthcare medications. The adoption of mass spectrometry in various industries continues to grow because of technological improvements in instrument sensitivity and miniaturization alongside research progress in proteomics and metabolomics. The biotechnology and pharmaceutical sectors represent essential market sectors that depend on mass spectrometry technology for their drug development operations, as well as their quality control assessments and biomarker discovery processes. The market benefits from regulatory requirements, which are growing more stringent because of environmental testing and food safety monitoring. Innovations in hybrid systems and user-friendly interfaces continue to reduce operational complexity and capital expenses, which make mass spectrometry technology more available to the market. The marketplace includes established organizations that boost their product ranges through strategic alliances and technological progress. The scientific research field, together with industrial quality control operations across multiple sectors, depends heavily on mass spectrometry, which secures its leading position in analytical instrumentation for future growth.
For instance, in December 2024, F. Hoffmann-La Roche Ltd released the Coba Mass Spec solution, which offers fully automated IVDR-compliant systems for routine labs. A rise in standardized clinical MS solutions has emerged due to the increasing demand for high-throughput systems that deliver expanded test menus.
Rising Demand in Precision Medicine Support Market Growth
The rising demand for precision medicine serves as a fundamental market force for mass spectrometry (MS) because MS delivers precise analysis of biomarkers, proteins, and metabolites required for individualized medical approaches. The high-precision molecular profiling abilities of MS provide accurate and sensitive results at a rapid pace for drug development and clinical diagnostics, and therapeutic monitoring. The enhancement of MS technologies through high-resolution and tandem MS enables their expanded utilization in drug development alongside clinical diagnostics and therapeutic monitoring processes. Pharmaceutical and biotech companies now use MS for pharmacokinetic studies and quality control to create precision drug formulations. Market growth receives additional support through government programs that fund personalized medicine research activities. The growing adoption of precision medicine will increase the need for modern analytical tools such as MS, which will lead to market growth and innovation over the next few years.
For instance, in June 2025, the American Society for Mass Spectrometry (ASMS) conference Thermo Fisher Scientific Inc. introduced its next generation mass spectrometry the Orbitrap Astral Zoom MS and Orbitrap Excedion Pro MS. The instruments work with advanced resolution capabilities and sensitivity which enable researchers to decode complex disease processes such as Alzheimer's and cancer thus leading to the discovery of fresh biomarkers and quicker development of precise medical treatments.
Technological Advancement Boosts Global Mass Spectrometry Market Demand
Modern technology innovations propel the mass spectrometry market growth. Businesses in the industry benefit from technological advancements, which include HRMS and portable miniaturized devices alongside AI-enabled data analysis systems. Pharmaceutical companies and environmental test facilities, and biotechnology laboratories use hybrid LC-MS and GC-MS systems along with modern ionization methods to detect substances more effectively. Workflow automation and cloud deployment enable organizations to cut operational expenses. Industries that require precise diagnostic tools and drug development capabilities, and food safety testing methods, attract market growth through advanced technological developments. The rising demand for dependable analytical instruments results in competitive advantages for companies that invest in R&D, thus expanding the global market share of mass spectrometry.
For instance, in June 2025, Water Corporation introduced its Xevo TQ Absolute XR tandem quadrupole mass spectrometer during the ASMS conference in Baltimore. The system uses the StepWave XR ion guide, which provides improved 6x sensitivity and robustness compared to previous models and decreases both power and gas requirements by half. The system's small footprint requires less laboratory space than its competitors in the market. The development demonstrates how technological progress boosts efficiency and operational effectiveness, which consolidates Waters' leadership in mass spectrometry markets.
Quadrupole Liquid Chromatography- Mass Spectrometry Hold the Largest Market Share
Quadrupole liquid chromatography-mass spectrometry (LC-MS) holds the largest market share due to the combination of its flexible operation and high sensitivity, and cost-effectiveness. LC-MS analysis serves the pharmaceutical industry and clinical diagnosis tests, as well as food safety protocols and environmental monitoring, as it delivers both quantitative and qualitative analytical capabilities. Triple quadrupole (QqQ) systems demonstrate exceptional stability in multiple reaction monitoring (MRM) mode, which makes them excellent for targeting the analysis of ultratrace compounds at precise levels. The adoption of quadrupole LC-MS by laboratories is increasing because such systems adhere to strict regulatory standards established by the FDA and EPA. The combination of reliability with ease of use and cost-effectiveness has made quadrupole LC-MS the standard choice for routine laboratories despite the advanced features of high-resolution mass spectrometers (HRMS). The evolution of ionization techniques, together with software integration, maintains the leading position of this technology in analytical workflows.
For instance, in June 2023, Agilent Technologies Inc. introduced two different liquid chromatography mass spectrometry systems (LC-MS), which include the Agilent 6495D LC/TQ and the Agilent Revident LC/Q-TOF. Agilent delivers superior performance with the Revident LC/Q-TOF system through their new Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software. The new technological advancements from Agilent allow customers to boost data quality and interpretation capabilities while reducing both time and human attention requirements, which makes it easier to meet changing market demands.
North America Dominates the Global Mass Spectrometry Market Size
The mass spectrometry market demonstrates a clear North American dominance through its robust research and development base, alongside substantial healthcare funding and extensive use of advanced analytical systems. The region receives large financial support for pharmaceutical and biotechnology research owing to growing requirements for drug discovery, along with precision medicine and clinical diagnostics. The market experiences additional growth due to the strict regulations that govern food safety, as well as environmental testing and forensic analysis. Investment by academic bodies alongside government institutions leads to better technology development, including portable and high-resolution mass spectrometers. The healthcare sector in North America, together with major pharmaceutical companies, generates a faster market adoption rate. The combination of growing proteomics and metabolomics applications with other factors maintains North America as the mass spectrometry market leader worldwide.
Pharmaceutical companies in the region are introducing new products to drive the expansion of the mass spectrometry market. For instance, at the ASMS conference in June 2024, Applied Biosystems (AB) SCIEX introduced the SCIEX 7500+ System, which includes their latest mass guard technology for mass spectrometry. The new ion-filtering system improves system durability and sample protection by blocking external contaminants and reducing instrument downtime and sensitivity maintenance across all sample types.
Impact of U.S. Tariffs on the Global Mass Spectrometry Market
The U.S. tariffs applied to all foreign goods, specifically those from China and the EU, will have substantial consequences for the mass spectrometry market worldwide, as they will drive up manufacturer costs and force buyers to pay higher instrument prices. The supply chain experiences disruptions and delays mainly because important components, such as detectors and vacuum systems, are sourced from these regions. The protective measures create a competitive advantage for American manufacturers, including Thermo Fisher and Agilent, while businesses that rely on Chinese and European suppliers will experience increased costs and lose market opportunities. The implementation of counter-tariffs by other nations will create difficulties for U.S. export activities, potentially altering the global trade landscape. The market can maintain stability due to continuous demand from pharmaceutical and biotechnology consumers. Businesses will establish new production facilities and create multiple supply chains to counter the negative effects of tariffs, yet consumers should expect immediate price increases alongside procurement waiting times.
Key Players Landscape and Outlook
The key players are committed to developing modern technologies that enhance mass spectrometry instruments for various industries, including pharmaceuticals, biotechnology, environmental testing, and food safety. The market experiences intensified competition due to specialized product offerings from small firms and new market participants. The market witnesses increased competition because small companies and new entrants provide specialized yet affordable products. The market expansion of companies occurs through strategic alliances and mergers, and acquisitions to establish broader market presence and improve technological capabilities. The market shows robust growth prospects because of rising needs for precise analysis, together with expanding clinical diagnostic applications and higher life science research funding. The future direction of the market will depend heavily on innovative developments combined with strategic business-to-business relationships.
For instance, in June 2025, Bruker Corporation publicized its acquisition of Biocrates Life Science AG as a method to strengthen its quantitative metabolomics Mass spectrometry solutions. Through this acquisition, Bruker improves its MS-based metabolomics solutions. The purchase strengthens Bruker's MS-based metabolomics solutions and enables the company to expand its operations into multiomics through instrument development and reagent production, and software and research service offerings, while incorporating the assets of proteomics technology developers PreOmics and Biognosys.
Spectrometry (MALDI-TOF)
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.